A number of proposed AML targets, including CD123, FLT-3, CLEC12A, and CLL-1, are actively being investigated, yet they all carry the risk of off-target toxicity due to expression on healthy tissues and cell types, or on hematopoietic stem cells (44–48). This evidence concerns the gene CLEC12A and acute myeloid leukemia.